G. K. Schwartz

Potentiation of Apoptosis by Treatment With the Protein Kinase C-Specific Inhibitor Safingol in Mitomycin C-Treated Gastric Cancer Cells

G. K. Schwartz, Adriana Haimovitz‐Friedman, S. K. Dhupar et al. · JNCI Journal of the National Cancer Institute · 1995 · 115 citations

Medicine, Oncology, Pharmacology +17

UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status.

Amreen Husain, Xiangming Yan, Néstor Rosales et al. · PubMed · 1997 · 56 citations

Medicine, Oncology, Pharmacology +17

Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060)

David R. D’Adamo, Mary Louise Keohan, Scott M. Schuetze et al. · Journal of Clinical Oncology · 2007 · 28 citations

Medicine, Oncology, Pharmacology +17

Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT).

Mark J. Ratain, G. K. Schwartz, Amit M. Oza et al. · Journal of Clinical Oncology · 2011 · 24 citations

Medicine, Oncology, Pharmacology +17

Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase.

Nicoletta Brega, Grant A. McArthur, Cedrik M. Britten et al. · Journal of Clinical Oncology · 2010 · 24 citations

Life Sciences, Pharmacokinetics, Pharmacology +17